
    
      Primary endpoint

      - To assess anti-tumour activity as change in tumour size at 8 weeks and the correlation with
      change in tumour ERK1/2 phosphorylation at day 10-14.

      Secondary endpoints

        -  Objective response rate to AZD4547 in all patients and in each tumour group

        -  Safety and tolerability of AZD4547 in all patients

        -  Disease control rate at 8 weeks

        -  Progression free survival in all patients and in each tumour group
    
  